Your browser doesn't support javascript.
loading
Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing TAVI for severe aortic stenosis: Insights from the WIN-TAVI registry.
Panoulas, Vasileios F; Chandrasekhar, Jaya; Busi, Gherardo; Ruparelia, Neil; Zhang, Zhongjie; Mehilli, Julinda; Sartori, Samantha; Lefèvre, Thierre; Presbitero, Patrizia; Capranzano, Piera; Tchetche, Didier; Iadanza, Alessandro; Sardella, Gennaro; Van Mieghem, Nicolas M; Meliga, Emanuele; Dumonteil, Nicolas; Fraccaro, Chiara; Trabattoni, Daniela; Sharma, Samin; Ferrer-Gracia, Maria-Cruz; Naber, Christoph K; Kievit, Peter C; Snyder, Clayton; Sutaria, Nilesh; Sen, Sayan; Malik, Iqbal S; Morice, Marie-Claude; Nihoyannopoulos, Petros; Petronio, Anna Sonia; Mehran, Roxana; Chieffo, Alaide; Mikhail, Ghada W.
Afiliação
  • Panoulas VF; Department of cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Chandrasekhar J; Faculty of Medicine, Cardiovascular Sciences, National Heart and Lung Institute, Imperial College London, London, UK.
  • Busi G; Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York, Box 1030, USA.
  • Ruparelia N; Interventional cardiology unit, San Raffaele Scientific Institute, Milan, Italy.
  • Zhang Z; Department of cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Mehilli J; Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York, Box 1030, USA.
  • Sartori S; Department of cardiology, Ludwig-Maximilians-University of Munich, Munich, Germany.
  • Lefèvre T; Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York, Box 1030, USA.
  • Presbitero P; Institut Cardiovasculaire Paris Sud, Hôpital privé Jacques cartier, Ramsay Générale de santé, Massy, France.
  • Capranzano P; Department of Cardiology, IRCCS Humanitas Clinical and Research Centre, Milan, Italy.
  • Tchetche D; Department of cardiology, University of Catania, Catania, Italy.
  • Iadanza A; Department of cardiology, Clinique Pasteur, Toulouse, France.
  • Sardella G; Emodinamica, Azienda Ospedaliera Universitaria Senese, Policlinico Le Scotte, Siena, Italy.
  • Van Mieghem NM; Interventional cardiology unit, Policlinico "Umberto I, Rome, Italy.
  • Meliga E; Department of interventional cardiology, Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands.
  • Dumonteil N; Interventional cardiology unit, Mauriziano Hospital, Turin, Italy.
  • Fraccaro C; Department of cardiology, Clinique Pasteur, Toulouse, France.
  • Trabattoni D; Interventional cardiology unit, University of Padova, Padova, Italy.
  • Sharma S; Invasive Cardiology Unit 3, Centro Cardiologico Monzino, IRCCS, Milan, Italy.
  • Ferrer-Gracia MC; Department of cardiology, Mount Sinai Hospital, New York, New York, USA.
  • Naber CK; Department of Cardiology, Interventional Cardiology Unit, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Kievit PC; Department of cardiology, Contilia Heart and Vascular Centre, Elisabeth Krankenhaus, Essen, Germany.
  • Snyder C; Department of cardiology, Radboud University Nijmegen Medical Center, Nijmegan,, The Netherlands.
  • Sutaria N; Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York, Box 1030, USA.
  • Sen S; Department of cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Malik IS; Department of cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Morice MC; Faculty of Medicine, Cardiovascular Sciences, National Heart and Lung Institute, Imperial College London, London, UK.
  • Nihoyannopoulos P; Department of cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Petronio AS; Faculty of Medicine, Cardiovascular Sciences, National Heart and Lung Institute, Imperial College London, London, UK.
  • Mehran R; Department of cardiology, Ludwig-Maximilians-University of Munich, Munich, Germany.
  • Chieffo A; Department of cardiology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Mikhail GW; Faculty of Medicine, Cardiovascular Sciences, National Heart and Lung Institute, Imperial College London, London, UK.
Catheter Cardiovasc Interv ; 97(3): 516-526, 2021 02 15.
Article em En | MEDLINE | ID: mdl-32865860
ABSTRACT

OBJECTIVE:

To evaluate the incidence, predictors and outcomes of female patients with patient-prosthesis mismatch (PPM) following transcatheter aortic valve intervention (TAVI) for severe aortic stenosis (AS).

BACKGROUND:

Female AS TAVI recipients have a significantly lower mortality than surgical aortic valve replacement (SAVR) recipients, which could be attributed to the potentially lower PPM rates. TAVI has been associated with lower rates of PPM compared to SAVR. PPM in females post TAVI has not been investigated to date.

METHODS:

The WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) registry is a multicenter registry of women undergoing TAVR for severe symptomatic AS. Two hundred and fifty patients with detailed periprocedural and follow-up echocardiographic investigations were included in the WIN-TAVI echocardiographic sub-study. PPM was defined as per European guidelines stratified by the presence of obesity.

RESULTS:

The incidence of PPM in our population was 32.8%. Patients with PPM had significantly higher BMI (27.4 ± 6.1 vs. 25.2 ± 5.0, p = .002), smaller sized valves implanted (percentage of TAVI ≤23 mm 61% vs. 29.2%, PPM vs. no PPM, p < .001) and were more often treated with balloon expandable valves (48.3 vs. 32.5%, p < .001) rather than self expanding ones (26.3 vs. 52.8%, <.001). BMI (OR = 1.08; 95%CI 1.02-1.14, p = .011) and valve size ≤23 mm (OR = 3.00 95%CI 1.14-7.94, p = .027) were the only independent predictors of PPM. There was no significant interaction between valve size and valve type (p = .203). No significant differences were observed in 1-year mortality or major adverse cardiovascular events.

CONCLUSIONS:

PPM in females undergoing TAVI occurs in one third of patients. BMI and valve size ≤23 mm are independent predictors. Larger registries are required to determine the impact of PPM on future clinical outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Implante de Prótese de Valva Cardíaca / Substituição da Valva Aórtica Transcateter Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Próteses Valvulares Cardíacas / Implante de Prótese de Valva Cardíaca / Substituição da Valva Aórtica Transcateter Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article